{
    "clinical_study": {
        "@rank": "146372", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablets"
            }, 
            {
                "arm_group_label": "PF-05180999", 
                "arm_group_type": "Experimental", 
                "description": "Modified-release tablets of PF-05180999"
            }
        ], 
        "brief_summary": {
            "textblock": "PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor.  The purpose of this study is\n      to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999\n      administered twice daily over 14 days.  Exploratory measures of PDE2 inhibition will also be\n      evaluated in blood and blister fluid."
        }, 
        "brief_title": "A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Migraine", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female (of non-childbearing potential) subjects between the ages\n             of 18 and 55 years\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)\n\n        Exclusion Criteria:\n\n          -  Subjects with Gilbert's disease or screening laboratory test results that deviate\n             from the upper and/or lower limits of the reference or acceptable range.  The\n             exception is that all liver function tests must not exceed the upper limit of normal.\n\n          -  Subjects with evidence of, or history of, hepatic disorder, including acute or\n             chronic hepatitis B or hepatitis C.\n\n          -  Subjects with very light skin or very dark skin (at the discretion of the\n             investigator)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981486", 
            "org_study_id": "B3441008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "BID modified-release tablets", 
                "intervention_name": "Placebo Tablets", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-05180999", 
                "description": "BID modified-release tablets (20 to 240 mg BID)", 
                "intervention_name": "PF-05180999 Tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PF-05180999", 
            "safety", 
            "tolerability", 
            "pharmacokinetics", 
            "migraine", 
            "PDE2", 
            "cAMP", 
            "cGMP", 
            "cantharidin", 
            "blister", 
            "CYP3A induction"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3441008&StudyName=A%20Study%20Of%20The%20Safety%2C%20Tolerability%2C%20And%20Pharmacokinetics%20Of%20Multiple%20Doses%20Of%20PF-05180999%20In%20Healthy%20Adults"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Placebo Controlled, Randomized, Subject-And Investigator-Blind, Sponsor-Open, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05180999 In Healthy Adult Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Single dose Cmax", 
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 1"
            }, 
            {
                "description": "Single dose Tmax", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 1"
            }, 
            {
                "description": "Single dose AUCtau", 
                "measure": "Area Under the Curve from Time Zero to end of dosing interval (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 1"
            }, 
            {
                "description": "Steady-state Cmax", 
                "measure": "Maximum Observed Plasma Concentration at Steady-State (Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 14"
            }, 
            {
                "description": "Steady-state Tmax", 
                "measure": "Time to Reach Maximum Observed Plasma Concentration at Steady-State (Tmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 14"
            }, 
            {
                "description": "Steady-state Cmin", 
                "measure": "Minimum Observed Plasma Trough Concentration at Steady-State (Cmin,ss)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 14"
            }, 
            {
                "description": "Steady-state AUCtau", 
                "measure": "Area Under the Curve from Time Zero to End of Dosing Interval at Steady-State (AUCtau,ss)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 14"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours post-final dose on Day 14"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours post-final dose on Day 14"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours post-final dose on Day 14"
            }, 
            {
                "description": "Ratio of Day 14 AUCtau to Day 1 AUCtau", 
                "measure": "Accumulation Ratio (Racc)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Days 1 and 14"
            }, 
            {
                "description": "Amount of drug excreted in urine", 
                "measure": "Amount Excreted in Urine (Ae)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 14"
            }, 
            {
                "description": "Percent of total dose excreted in urine", 
                "measure": "Percent of Dose Excreted in Urine (Ae%)", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 14"
            }, 
            {
                "description": "Renal clearance is a quantitative measure of the rate at which a drug substance is removed from the blood via the renal route.", 
                "measure": "Renal Clearance (CLr)", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours post-dose on Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981486"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Metabolite identification", 
                "measure": "Identification of metabolites of PF-05180999 in urine and plasma", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 14"
            }, 
            {
                "description": "Leukocyte levels in blister fluid and blood", 
                "measure": "Change from Baseline in Total Leukocyte Levels and Leukocyte Subpopulations in Blister Fluid and Blood", 
                "safety_issue": "No", 
                "time_frame": "Day 13 and Day 14"
            }, 
            {
                "description": "Cytokine levels in blister fluid", 
                "measure": "Change from Baseline in Cytokine Levels in Blister Fluid", 
                "safety_issue": "No", 
                "time_frame": "Day 13 and Day 14"
            }, 
            {
                "description": "Time-averaged area under the effect curve", 
                "measure": "Time-Averaged Area Under the Effect Curve (AUEC/t) for Platelet cGMP and cAMP", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 1 and Day 14"
            }, 
            {
                "description": "Ratio of Day 14 AUEC/t to Day 1 AUEC/t", 
                "measure": "AUEC/t Ratio", 
                "safety_issue": "No", 
                "time_frame": "0-12 hours post-dose on Day 1 and Day 14"
            }, 
            {
                "description": "Urinary marker of CYP3A induction", 
                "measure": "Urinary 6beta-hydroxycortisol/cortisol ratio", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "Plasma marker of CYP3A induction", 
                "measure": "Plasma 4beta-hydroxycholesterol/cholesterol ratio", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}